health · family: the solution exists but nobody can afford it
nobody wants to makethe drug we need most
The antibiotic pipeline is collapsing because the drugs with the greatest societal value have the lowest commercial value
Problem statement
Antimicrobial resistance in bacteria killed an estimated 1.27 million people in 2019 — more than HIV or malaria. Yet the pharmaceutical industry is abandoning antibiotic development: WHO writes that "most major pharmaceutical companies have left the antibiotic research and development space and many smaller antibiotic companies are struggling to survive." The economics are inverted: failure rates in antibiotic development are high, and, in WHO's words, "the costs incurred in research and development stand against limited potential revenues from taking a new antibiotic to market." For reserve antibiotics, which must be used sparingly, WHO asks governments to explore models in which procurement and reimbursement are "linked to availability instead of volume." The WHO's 2020 TPPs for antibacterial agents target four clinical syndromes for which WHO says new therapies are urgently needed, and WHO itself warns that much more is needed to keep the pipeline from drying up completely.
Why this matters
Six bacterial species alone — E. coli, S. aureus, K. pneumoniae, S. pneumoniae, A. baumannii, P. aeruginosa — were each responsible for more than 250,000 deaths associated with antimicrobial resistance in 2019. The highest death rate attributable to resistance was in western sub-Saharan Africa (27.3 per 100,000). The clinical pipeline is thin: when WHO wrote its gonorrhoea TPP, only two new antibiotics (zoliflodacin and gepotidacin) were in clinical development for that infection, a pipeline WHO called "severely depleted due to lack of economic attractiveness and recent failures in Phase 3 clinical studies." Murray and colleagues add that, over the past few decades, investments in the antibiotic pipeline "have been small compared with those in other public health issues with similar or less impact."
What’s been tried and why it hasn’t worked
Volume-based pharmaceutical business models conflict with antibiotic stewardship, which WHO calls "essential to preserve the effectiveness of any new antibacterial treatment." Reserve antibiotics must be used sparingly, creating a fundamental conflict between public health value and commercial value; the TPPs therefore ask governments to explore models in which procurement and reimbursement for reserve antibiotics are "linked to availability instead of volume to foster appropriate use." Discussions in the G7, the G20 and other international fora have led to a number of new publicly funded research initiatives, and WHO's 2017 priority pathogens list and these TPPs exist to point that work at priority public health needs. But WHO does not present them as sufficient: "Much more is needed to ensure that the antibacterial drug pipeline does not dry up completely."
What would unlock progress
The WHO TPPs define what drugs are needed: oral agents for enteric fever (oral, or oral plus intravenous), gonorrhoea (oral or intramuscular, single dose preferred) and uncomplicated UTI; intravenous agents for children including neonates with multidrug-resistant Gram-negative infections; and, across the profiles, low or no cross-resistance to existing antibiotic classes, which the gonorrhoea and UTI profiles tie to a new class, new target or new mode of action. The bottleneck is not primarily technical but economic-structural. When the TPPs were written, only two new antibiotics, zoliflodacin and gepotidacin, were in clinical development for gonorrhoea, and the oral agents in development for UTI (sulopenem, tebipenem) were, in WHO's words, "mainly modified compounds of old classes." But without the availability-linked procurement and reimbursement models the TPPs ask governments to explore, each new antibiotic faces the same limited potential revenues that WHO says have driven most major companies out of the field.
Entry points for student teams
A team could model the economic dynamics of antibiotic development under different incentive structures — subscription payments, milestone prizes, transferable exclusivity vouchers — using Monte Carlo simulation of clinical trial outcomes, market adoption, and resistance evolution. The question is: which policy mechanism minimizes the probability of pipeline collapse while maintaining stewardship? Alternatively, a team could design a prototype rapid AST (antimicrobial susceptibility testing) device that enables narrower-spectrum prescribing, reducing the need for broad-spectrum reserve antibiotics and potentially improving their commercial viability by reducing stewardship-imposed volume restrictions. Relevant disciplines: health economics, policy, biomedical engineering, infectious disease.
Genes
Structural cousins: stuck the same way, in other fields
Sources
WHO, "Target product profiles for needed antibacterial agents: enteric fever, gonorrhoea, neonatal sepsis, urinary tract infections and meeting report," 2020, ISBN 978-92-4-000389-7. Murray CJ et al., "Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis," The Lancet 399(10325):629-655, 2022. )02724-0/fulltext go to source 1 ↗ go to source 2 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
- Structurally analogous to any domain where the optimal social use of a product (conservation/stewardship) directly conflicts with the revenue model (volume-based sales). Parallels exist in fisheries management, water rights, and spectrum allocation.
- The 2020 WHO TPPs are unusual in that the binding constraint is not "we don't know what to build" but "we can't sustain the economics of building it."
Reconciliation 2026-09-30: Fact repair after reading the whole write-up against both sources it names. The WHO target product profiles were read in full on 2026-09-30: the publication page at https://www.who.int/publications/i/item/9789240003897 and the 32-page PDF it links to (https://iris.who.int/server/api/core/bitstreams/426b372c-3c98-4ffa-b58f-4aa279589399/content). The Lancet page for Murray et al. 2022 returned a 403 to automated access, so the paper was read in full from its PubMed Central copy (https://pmc.ncbi.nlm.nih.gov/articles/PMC8841637/), and its citation was checked against the Crossref record for the DOI 10.1016/S0140-6736(21)02724-0. (1) The Source line gave the Murray title without its subtitle; the record's full title, "Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis," is now used. Authors, journal, volume, issue, pages and year matched. (2) The text said projections estimate 39 million cumulative deaths by 2050. Neither source contains that figure (Murray et al. mention only the earlier estimate of 10 million deaths a year by 2050 and note that it has been criticised); the clause was removed. (3) The text said Novartis, Sanofi, AstraZeneca and Bristol-Myers Squibb had exited antibiotic R&D, leaving only four major companies with active programs. No source names these companies or gives that count; the sentence now quotes the WHO page, which says most major pharmaceutical companies have left the field and many smaller companies are struggling to survive. (4) The text said a new antibiotic costs about $1.5 billion to develop and earns average annual revenues of $46 million. Neither source gives these figures; the sentence now quotes the WHO page on high failure rates and R&D costs standing against limited potential revenues, and the TPPs' request that governments explore procurement and reimbursement "linked to availability instead of volume" for reserve antibiotics. (5) The Achaogen and plazomicin story (15 years, FDA approval, WHO listing, under $1 million in six months, bankruptcy) appears in neither source; it was removed from the Problem Statement, from the last sentence of What Would Unlock Progress, and from the first working note above. (6) The text said the 2020 TPPs "remain largely unfilled"; a 2020 document cannot say that, and Murray et al. do not. The sentence now says the TPPs target four clinical syndromes for which WHO says new therapies are urgently needed and that WHO warns much more is needed to keep the pipeline from drying up. (7) The six leading pathogens were said to cause over 250,000 deaths "each per year from resistant infections." Murray et al. say each was responsible for more than 250,000 deaths associated with resistance in 2019 (the broader of the paper's two measures; the six together account for 929,000 of the 1.27 million attributable deaths). The sentence now uses the paper's wording. The opening sentence now says "in bacteria" and "an estimated," as the paper does, and "HIV/AIDS" became "HIV" to match the paper's comparison. (8) The highest death rate was placed in "sub-Saharan Africa"; the paper gives 27.3 per 100,000 for western sub-Saharan Africa, attributable to resistance. Corrected. (9) Removed because neither source contains them: 97 agents in the clinical pipeline, 12 innovative, 4 against critical pathogens; 82% of researchers leaving the field between 2018 and 2023; collapse within 4 to 8 years; net present value of minus $50 million versus plus $1.15 billion for a musculoskeletal drug; venture capital of $1.6 billion versus $26.5 billion for oncology in 2011 to 2020; CARB-X and BARDA; the AMR Action Fund of about $1 billion; the UK subscription model at up to 20 million GBP a year, launched in 2024 as the world's first delinked payment; the US PASTEUR Act at $6 billion over 10 years; GARDP advancing zoliflodacin and cefepime-taniborbactam; gepotidacin being GSK's and in Phase 3. In their place the text now carries what the sources do say: the gonorrhoea pipeline was "severely depleted due to lack of economic attractiveness and recent failures in Phase 3 clinical studies," with only zoliflodacin and gepotidacin in clinical development; the oral UTI agents in development (sulopenem, tebipenem) were "mainly modified compounds of old classes"; investments in the pipeline have been small compared with other public health issues of similar or less impact (Murray et al.); and G7 and G20 discussions led to new publicly funded research initiatives that the 2017 priority pathogens list and these TPPs are meant to guide. (10) The cause sentence "business models fail because antibiotic stewardship ... directly undermines commercial returns" was softened to say volume-based models conflict with stewardship, which WHO calls essential, and to give the TPPs' own remedy. (11) The parenthetical on what the TPPs ask for said "IV agents for neonatal sepsis; novel mechanisms of action against critical pathogens." The TPP meeting renamed the neonatal profile to therapy for children including neonates with MDR Gram-negative infections (intravenous, with oral step-down preferred), the gonorrhoea route is oral or intramuscular with a single dose preferred, and the profiles ask for low or no cross-resistance to existing classes, which the gonorrhoea and UTI profiles tie to a new class, target or mode of action; "critical pathogens" is not the TPPs' wording. The parenthetical now follows the document. Confirmed in the sources and left as written: 1.27 million deaths in 2019; more deaths than HIV or malaria; the six species and their order; the four syndromes (enteric fever, gonorrhoea, neonatal sepsis, UTI); stewardship as the public health response and the conflict with volume-based revenue; the WHO citation (title, year, ISBN); the entry points, which name no source. Could not be checked against these sources and was left as the write-up's own framing: that the bottleneck is economic-structural rather than technical, and the analogies to fisheries, water rights and spectrum allocation in the working notes. The spelling "gonorrhoea" in the Source line follows the PDF; the WHO web page spells it "gonorrhea." No title changed. Genome tags untouched. A second reader went over these repairs on the same day, reading the WHO page, the WHO PDF, the PubMed Central copy of Murray et al. and the Crossref record independently; every repair stood, and three phrases were tightened to the sources' own scope: "thin where the need is greatest" became "thin" (the TPP says only that the gonorrhoea pipeline is severely depleted); the UTI profiles list "new class/target/mode of action" without the gonorrhoea profile's "best achieved by," so the sentence now says both profiles "tie" cross-resistance to those; and "limited revenues" became "limited potential revenues," the WHO page's phrase.